NCT05546918 (UpcomingVoice) is a clinical trial of survey, interviews and focus groups in COVID-19, sponsored by Luxembourg Institute of Health.

Who is sponsoring NCT05546918?

NCT05546918 is sponsored by Luxembourg Institute of Health.

What drugs are being tested in NCT05546918?

Interventions in NCT05546918: survey, interviews and focus groups.

What condition does NCT05546918 study?

NCT05546918 studies COVID-19, Post-Acute COVID-19.

Is NCT05546918 still recruiting?

NCT05546918 is currently completed. Last updated 9 February 2024.

Last reviewed 2024-02-09 · How we verify

NCT05546918: UpcomingVoice

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Co-design of a Digital Health Solution to Monitor Persisting Symptoms Related to COVID-19 Using Voice

Completed Last updated 9 February 2024

What this trial tests

trial testing survey, interviews and focus groups in COVID-19 in 125 participants. Completed in 8 February 2024.

Timeline

1 October 2022

Primary endpoint
8 February 2024

8 February 2024

Quick facts

Lead sponsor	Luxembourg Institute of Health
Status	Completed
Study type	OBSERVATIONAL
Enrollment	125
Start date	1 October 2022
Primary completion	8 February 2024
Estimated completion	8 February 2024
Sites	1 location across Luxembourg

Drugs / interventions tested

survey, interviews and focus groups

Conditions studied

COVID-19 — all drugs for COVID-19 →
Post-Acute COVID-19 — all drugs for Post-Acute COVID-19 →

Sponsor

Luxembourg Institute of Health

Who can join

18 and older, any sex, with COVID-19 or Post-Acute COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The UpcomingVoice project aims to co-design a digital health solution based on vocal biomarkers for screening and self-monitoring of frequently reported COVID-19-related symptoms with its end-users: 1) people with persisting COVID-19 related symptoms, with or without a Long COVID diagnosis and 2) healthcare professionals involved in the care of Long COVID patients. To achieve this objective the UpcomingVoice study will determine: * The needs, expectancies, acceptability, fears, barriers and leverages of the end-users regarding the use of voice to self-monitor or screen for Long COVID symptoms * The specifications that such a mobile application should meet in order to be considered acceptable and effective by its intended users in terms of technological aspects (type of device, type of voice recordings…), frequency of utilisation, design etc. The project consists in 2 separate parts : one anonymous online survey and one qualitative part based on semi-structured interviews and focus groups. The results of this study will be the specifications of a voice-based digital health solution.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Co-Design of a Voice-Based Digital Health Solution to Monitor Persisting Symptoms Related to COVID-19 (UpcomingVoice Study): Protocol for a Mixed Methods Study.
Fischer A, Aguayo GA, Oustric P, Morin L, et al · · 2023 · cited 1× · PMID 37335611 · DOI 10.2196/46103

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Luxembourg Institute of Health trials

Trials by the same sponsor.

NCT07500259 — Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and P · not yet recruiting
NCT06235684 — Clinnova-RD: A Prospective Cohort Study of Patients With Rheumatoid Diseases · not yet recruiting
NCT07156994 — Development of Voice Biomarkers of Frequent COVID-19 and Long Covid-related Symptoms Based on Data From Users of the Lon · not yet recruiting
NCT06816147 — HealthyW8_60+ Pilot · NA · recruiting
NCT06384872 — Effect of Shoe Cushioning Position and Properties on Running-related Injury Risk · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05546918 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Luxembourg Institute of Health
Last refreshed: 9 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05546918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing